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ILLUSTRATIVE CASE HISTORY 
A 14-year-old Caucasian boy presented with a 4-week 
history of malaise, intermittent fever, tender lymph- 
adenopathy of the axillary and cervical nodes, and 
fatigue which had been interfering with his school 
work. He had previously been healthy, with no 
developmental problems or past medical history, except 
for tonsillectomy at the age of 8 years. On direct 
questioning, he denied loss of appetite or a reduction 
in weight; there had been no rash or other type of 
cutaneous lesion. His father, mother and two younger 
siblings were well and asymptomatic. He had last been 
on holiday with the entire family 4 months previously 
in Greece. Family pets included his father's tropical fish, 
a hamster, and an aging cat. 
Examination failed to detect any signs other than 
the lymphadenopathy. The patient was afebrile. Investi- 
gation revealed normal biochemistry, haemoglobin 
concentration and platelet count, but the total white 
cell count was raised, at 1 2 . 4 ~  109/L, with a neutro- 
philia of 96%. The erythrocyte sedimentation rate was 
39 mm/h. The chest X-ray was unremarkable. 
Histologic examination of a lymph node demon- 
strated caseating granulomata, and a specific stain 
confirmed the diagnosis. Routine cultures of blood 
and node homogenate were negative at 7 days, and the 
specimens were discarded. 
With appropriate management, the boy complete- 
ly recovered within the next 2 months. 
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Thoughts on the case 
0 What was the most likely diagnosis? 
How could investigation have been optimized? 
0 What was the nature of the successful management? 
MULTIPLE-CHOICE QUESTIONS 
In each o f t h e  numbered questions, a t  least one, and up tojive, 
o f  the individual entries are correct. 
( T h e  answers are a t  the end o f  this article.) 
1. Regarding cat scratch disease (CSD) 
(a) The first reports of lymphadenopathy 
following animal contact date 
back to the 1880s. True/False 
generally accepted to be Bartonella 
henselae. True/False 
(c) The primary reservoir for the organism 
is the adult cat, especially if elderly or 
diseased. True/False 
infection to humans has been shown 
to be the cat flea. 
occur at age less than 21 years. 
(b) The causative organism is now 
(d) The vector of transmission of 
True/False 
True/False 
(e) Eighty per cent of cases of CSD 
2. Concerning the clinical features 
and natural history of CSD 
(a) A history of contact with cats is 
essential to make the clinical diagnosis 
of CSD. True/False 
(b) It is not uncommon for the primary 
skin lesion not to be detected on 
clinical examination. True/False 
(c) Lymphadenopathy is almost always 
present. True/False 
(d) In the immunocompetent patient, 
CSD can lead to complications in 
almost every organ system. True/False 
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(e) CSD requires treatment with oral 
antibiotics such as doxycycline or 
ciprofloxacin. True/False 
3 .  Bartonella spp. are increasingly 
recognized as causes of human 
infection. The following statements 
are correct 
(a) Four species have been implicated 
in causing human illness. True/False 
(b) Prior to the 1990s, members of this 
genus (as now named) were associated 
only with the arthropod-borne 
infections Carrion’s disease and trench 
fever. True/False 
(c) Bartonella spp. have been implicated in 
the etiology of a specific syndrome 
characterized by cutaneous lesions 
called bacillary angiomatosis. True/False 
of ‘culture-negative’ endocarditis. True/False 
fever due to bartonella infection is seen 
only in immunosuppressed patients. True/False 
(d) Bartonella spp. are recognized causes 
(e) Prolonged bacteremia with relapsing 
4. Regarding the microbiology of 
(a) Members of t h s  genus are obligate 
(b) B. henselae is an aerobic, non-motile, 
Bartonella spp. 
intracellular pathogens. True/False 
oxidase- and catalase-negative, Gram- 
negative rod. True/False 
(c) The species causing human infections 
can be divided into two groups on 
the basis of differential phenotypic 
properties. True/False 
(d) Identification to the genus level is 
relatively straightfonvard, but 
identification to the species level 
requires genotypic methods. True/False 
(e) Acridine orange is a useful diagnostic 
stain. True/False 
5. The following statements concerning 
the isolation of Bartonella spp. are correct 
(a) Cell-culture systems are the proven 
optimal method for isolation of 
Bartonella spp. True/False 
inoculation of blood or lymph node 
aspirate directly onto standard agar 
media. True/False 
MacConkey agar. True/False 
(b) Bartonella spp. can be cultured by 
(c) Bartonella spp. will not grow on 
(d) Detection of COz production by 
standard automated blood culture 
systems should not be relied upon as a 
means of detecting growth. True/False 
pit and strongly adhere to the agar. True/False 
(e) On primary isolation, colonies often 
6. With respect to non-cultural 
diagnosis of bartonella infections 
(a) Warthin-Starry silver staining of biopsy 
specimens is useful in demonstrating the 
organisms. True /False 
lesions of bacillary angiomatosis (BA) 
and CSD. True/False 
antigen results in a delayed-type hyper- 
sensitivity reaction in >90% of 
infected individuals. True/False 
(d) Infection results in a species-specific 
antibody response detectable by 
indirect immunofluorescent antibody 
(IFA) assay. True/False 
(e) Restriction fragment length poly- 
morphism (RFLP) analysis of the 
citrate synthase gene is a useful means 
of identifying bartonellae to the 
species level. True/False 
(b) Granuloma formation is seen in the 
(c) In CSD, intradermal injection of 
DISCUSSION 
Question 1 
(a) Parinaud in 1889 first observed the development of 
conjunctival inflammation and preauricular lymph- 
adenopathy in patients following animal contact [l]. 
More specifically, in the 1930s, Foshay in the USA, and 
Debre in France reported cases of regional lymph- 
adenopathy resulting from cat scratches, and in the 
following decade Hanger and Rose purified a slun 
test antigen from the lesion of such a patient [l]. The 
term cat scratch disease was eventually adopted in 
recognition of the syndrome by Debre et al in their 
publication of 1950, entitled ‘La maladie des griffes 
du chat’ [2]. 
(b) Rochalimaea henselae was declared a new species in 
1992 [3,4] on the basis of 16s rRNA gene sequencing 
and DNA-DNA hybridization studies of Rochalimaea- 
like organisms which had been isolated from the 
blood of patients presenting with febrile illnesses, first 
described by Slater et al in 1990 [5]. Subsequently, the 
genus was merged with Bartonella (see answer to Q3a). 
Although CSD has been a recognized clinical 
entity since Debre’s description, it was not until 1983 
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that bacilli were actually demonstrated within affected 
tissue by Warthin-Starry silver staining of lymph nodes 
[6]. Modified Gram stain of these organisms showed 
them to be slender, pleomorphic, Gram-negative rods. 
Subsequently, identical organisms were identified in the 
skin at the primary inoculation site [7]. In 1988, English 
et al successfully cultured a fastidious Gram-negative 
bacdus from the lymph nodes of 10 patients of a group 
of 19 clinically diagnosed with CSD [8]. Subsequently, 
it was proposed that this organism, presumed to be the 
cause of CSD, should be named Ajpia felis after the 
Armed Forces Institute of Pathology (AFIP), where 
the discovery of the organism had been made. 
In the same year that Wear et al [6] demonstrated 
the presence of bacteria in lymph node tissue from 
patients with CSD, Stoler et al described a novel 
syndrome of angioproliferative subcutaneous nodules 
in association with fever, sweats, diarrhea and weight 
loss in an HIV-positive individual [9]. Staining of tissue 
sections of a nodule revealed argyrophilic bacteria 
throughout the interstitium. The nodules responded to 
treatment with erythromycin. Further reports of this 
syndrome, later to be named bacillary angiomatosis 
(BA), followed [lo]. Subsequently, in the same year that 
English et al cultured their bacillus from CSD lymph 
nodes, LeBoit et al, using the Warthin-Starry silver 
stain on identical angioproliferative lesions from seven 
patients with AIDS [ll] ,  demonstrated bacilli with a 
staining pattern indistinguishable from that of the 
original organisms described by Wear et al. They also 
reported resolution of these nodules with antibiotics, 
either erythromycin or a combination of rifampicin 
and isoniazid. In the light of these discoveries, it 
became widely accepted that the causative agents of 
CSD and BA were the same organism, presumed to be 
A.  felis. 
In 1990, Relman et a1 [12], amplified andsequenced 
16s rRNA gene fragments directly from tissue samples 
of BA lesions from four patients, and identified an 
organism which had 98.3% 16s rRNA homology with 
Rochalimaea quintana. In 1990 also, Slater et al [5], using 
EcoRV restriction endonuclease digestion of whole 
DNA of organisms cultured from the blood of five 
patients with febrile illnesses, and found to have whole 
cell fatty acid composition closely resembling that of R. 
quintana, demonstrated a common banding pattern 
between the isolates which differed from that of R. 
quintana. The organism was later named R. henselae 
K41. 
Further work has favored this organism, rather than 
A. felir, as the cause of CSD. Serologic studies have 
repeatedly demonstrated a lack of antibody response 
to A.@lis in patients with CSD [13-151. Between 84% 
and 88% of patients with CSD have a titer of 1 : 64 or 
greater in the immunofluorescent antibody test (IFAT) 
against B. (R.) henselae, compared with 3% of controls 
[16,17]. Polymerase chain reaction (PCR) has detected 
DNA in the lymph nodes of a similar percentage of 
CSD patients [18,19]. Antigen preparations for diag- 
nostic skin testing have also been shown by PCR to 
contain the DNA of B. henselae rather than that of 
A. felis [20]. B. henselae has also been cultured from the 
lymph nodes ofpatients with CSD [21,22]. By contrast, 
there is no evidence to suggest that other species of 
Bartonella have a causal role. 
However, the fact that evidence of B. henselae 
infection is lacking in a significant proportion of cases, 
and the fact that A.felir has been demonstrated in some 
lesions, means that debate persists as to the definite 
etiology [23]. It may be that CSD is caused by more 
than one agent, and that A. felis is simply less com- 
monly implicated. Alternatively, A. felis may be the 
cause of a CSD-like syndrome. 
(c) The role of cats in the transmission of CSD is well 
established [17,24-291. Kordick et a1 [27] observed B. 
henselae bacteremia in 25% of a sample of 24 healthy 
cats, compared with 84% of 19 cats whose owners were 
diagnosed as having CSD. Similarly, Chomel et a1 [24] 
reported a bacteremia rate among 146 healthy cats of 
37%, compared with seven out of 10 cats implicated in 
cases of CSD or BA. Thus bacteremia was determined 
to be a risk factor for CSD. It has also been demon- 
strated that kittens under 12 months of age are more 
likely than older cats (with serologic evidence of past 
infection) to be bacteremic 124,251, thereby implicating 
kittens rather than adult cats as the primary reservoir 
for infection. Zangwill et al [17] noted that patients 
with CSD were 15 times more likely than controls to 
own a kitten, 27 times more likely to have been bitten 
or scratched by a kitten, and 29 times more likely to 
have at least one kitten with fleas. Demers et al directly 
and specifically link CSD with kittens [25]. In the 
illustrative case at the beginning of this article, the 
probable source of this patient’s infection was not his 
own cat, but the kitten which his best friend had 
recently been given! 
(d) It has been shown that bacteremic cats are more 
likely to be infested with the cat flea (Ctenocephalides 
felis) than non-bacteremic cats [24]. Also, by using an 
artificial feeding device, it has been demonstrated that 
B. henselae is able to replicate and persist in the cat flea 
1301. Experimental transmission between cats has been 
achieved using a flea vector (311, but direct transmission 
from cat to human has not been demonstrated. It is, of 
course, entirely possible [32], considering the known 
arthropod vectors involved in two other bartonella 
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infections (see answer to Q3b). There is some epidemio- 
logic evidence linking B. henrelae infection with tick 
bites [33] but no clear connection has been demon- 
strated. 
(e) CSD is primarily a disease of children and young 
adults. Eighty per cent of cases occur below the age of 
21 years [34,35], with a peak incidence between 2 and 
14 years. In the USA, there are an estimated 24 000 
cases of CSD per year [23]. Seasonal variation is noted, 
most cases occurring in the autumn and winter [34, 
361. Clustering of cases has been documented within 
families, usually coincident with the acquisition of a 
new pet 1231. 
Question 2 
(a) Before serologic and genotypic methods were avail- 
able for the diagnosis of CSD, a clinical diagnosis was 
established if three of the four following criteria were 
fulfilled: (1) contact with a cat resulting in a primary 
lesion; (2) a positive skin test; (3) lymphadenopathy in 
the absence of any other cause; and (4) characteristic 
histopathology of a lymph node [37]. By definition, 
therefore, a history of contact with cats is not essential 
to the clinical diagnosis. A small proportion of patients 
provide no such history [37,38]. 
(b) Reports vary as to the percentage of patients pre- 
senting with primary skin lesions, from 25% [I71 to 
94% [37]. The lesion, a pustule or papule at the site of 
injury, may have resolved by the time medical attention 
is sought, but Carithers et al noted that many lesions 
may not be readily apparent, e.g. if situated on the scalp, 
and that a thorough search is often necessary [37]. A 
large study of the presenting features of 1174 cases of 
CSD over a 29-year period 1361 cites the presence of 
an inoculation lesion in 58.6%. 
(c) Lymphadenopathy occurs in 100% of cases [35,36], 
although between 5% and 20% of cases present because 
of other manifestations [23]. Lymphadenopathy is the 
sole presenting sign in approximately 45-50% [35,36]. 
Other clinical signs include: fever of 38-41OC and 
malaise in -30%; anorexia and headache in -15%; 
splenomegaly in -10%; and rash and conjunctivitis in 
4-6% [35,36]. 
(d) Typically, CSD is a benign infection which begins 
with the formation of a pustule or papule at the site of 
inoculation 4-6 days after a cat scratch or bite [l]. 
Regional lymphadenopathy, tender in most patients, 
develops within 7-50 days of the appearance of the 
primary lesion. Eighty per cent of the involved nodes 
are located in the head, neck, and axillary areas [l]. In 
approximately 15% of cases, the lymphadenopathy is 
suppurative [l]. Spontaneous resolution within 2-6 
months is the rule [35,36]. 
Reports vary as to the incidence of ‘complica- 
ted’ CSD. Margileth et a1 [36] observed ‘typical’ 
infection in 88.4% of the cases studied, and ‘atypical’ 
or ‘complicated’ infection in 11.6%. The commonest 
complication was Parinaud’s oculoglandular syndrome 
(POS), with an incidence of 6.4%. However, rates 
of POS have been reported from 2% up to 17% 
[39,40]. POS presents either as conjunctivitis with 
parotid swelling caused by lymphadenitis, or as an 
ocular granuloma. Recovery without sequelae in 2-4 
months is the usual outcome [23]. 
Other complications include hepatic and splenic 
abscesses, pneumonia and pleural effusion, osteo- 
myelitis, paravertebral abscess, and neurologic involve- 
ment (references cited in Anderson [23)). . A recent 
article describes a case of CSD mimicking pancreatic 
malignancy 1411. 
Neurologic manifestations occur in I-7% of 
patients, most commonly as an acute encephalopathy 
presenting with fever, agitation, confusion, twitching, 
and even status epilepticus and coma [23,34,42,43]. 
Children aged 7-12 years are at greatest risk [43,44]; 
intrathecal antibody production to B. henselae is detect- 
able in the cerebrospinal fluid (CSF) [45]. Most patients 
recover rapidly, usually within 14 days [23]. Other 
neurologic complications include aseptic meningitis, 
neuroretinitis, cranial and peripheral neuropathies, 
myelitis, and meningoencephalitis [22, 231. 
(e) Data concerning in vitro activity of antibiotics 
against Bartonella spp., and their clinical efficacy, are 
sparse because of the limited number of isolates and 
cases. Maurin et a1 [46] determined the MICs of a wide 
range of antimicrobials for 14 Bartonella isolates by agar 
dilution. Table 1 summarizes the data for commonly 
used agents. The E-test has also been used to assess in 
vitro susceptibilities [47]. 
Another study, using a cell-culture bactericidal 
assay system with murine macrophage-like cells and 
human endothelial cells, demonstrated that, among 
many antimicrobials, only gentamicin, tobramycin and 
amikacin possessed bactericidal capabihty [48]. 
The use of antibiotics in the treatment of un- 
complicated CSD is of questionable value, and is not 
generally recommended [23,35,49]. In the context of 
complicated infection, there may be some benefit to be 
gained. Margileth et al [36] reported in detail on 23 
immunocompetent adults who had prolonged severe 
CSD with constitutional symptoms (e.g. malaise, fatigue, 
anorexia, weight loss) and lymphadenopathy for between 
2-3 weeks and over 2 years. Eighteen patients had fever, 
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Table 1 
Antibiotic MIC9o (mg/L) 
Penicillin, mioxycilliii 0.06 
Cefotaxiine, ceftazichnie 0.25, 0.5 respectively 
Iniipeneni 0.5 
Gentanlicin, tobramycin, aniikacin 
Azithroiycin, clarithromycin, 0.015, 0.015, 0.12 human disease [23]. 
One  other species is reported to have caused 
human infection: a single case of infective endocarditis 
caused by B. elizabethue has been reported [52]. The 
other members of the genus, B. vinsonii (the ‘Canadian 
vole agent’), B. grahamii, B. tuylorii, B. doshiae, B. tulpae 









0.12, 2, 8 recpectivcly 
Doxycycl1ne 0.12 
from 38.3’ to 40.6 ‘C, lasting from 2 days to 2 months. 
The remaining five were afebrile throughout. Five 
patients had systemic complications in the form of 
neuroretinitis, pleurisy, arthritis, splenic abscesses, 
mediastinal lymphadenopathy, and enlarged nodes at 
the head of the pancreas. Treatment with oral anti- 
biotics such as ampicillin, co-trimoxazole, erythro- 
mycin and tetracycline was started in 18, and had no 
effect on the duration or severity of the illness. One 
patient who developed shock and a convulsion required 
the addition of tobramycin and cefotaxime, to which 
the patient is reported to have responded. All patients 
recovered completely. 
Another paper reports the rapid response of three 
patients with complicated CSD (two had extensive 
hepatic involvement; one had marked, painful regional 
lymphadenopathy) to intravenous gentamicin [49]. 
Note that there is a distinction to be made between 
the syndrome of ‘complicated CSD’ in the immuno- 
competent patient, in which the usual outcome is 
spontaneous recovery, and the syndrome of relapsing 
fever in the immunocompetent due to prolonged 
bacteremia with either B. henselae or B. quintanu, which 
would require treatment (see answer to Q3e). CSD 
in the immunosuppressed, on the other hand, can lead 
to disseminated and life-threatening infection necessi- 
tating treatment [50] (see answer to Q3c). 
Question 3 
(a) Until recently, the genus Bartonella contained only 
a single species, B. bacillformis. In 1993, it was proposed 
to unite the genus with another, Rochalimaea, on the 
basis of DNA-DNA hybridization studies and 16s 
rRNA sequencing analysis 1511. At the time, perhaps 
the best-known species within the genus Rochalimaea 
was R. quintana, now Bartonella quintana. R .  henselae had 
just been identified as a cause of bacterernia in patients 
with febrile illnesses, and was being mooted as the 
cause of CSD. 
(b) Carrion’s disease is caused by B. bacillformis. It 
is found only in Peru, Ecuador and Columbia. The 
bacterium is transmitted by the Peruvian sandfly, 
Lutzomyiu verrucurum, and infection results in a biphasic 
disease characterized by an acute stage called Oroya 
fever, which is a life-threatening hemolytic illness, 
followed by a chronic stage termed verruga peruana. 
This second phase is manifested by the appearance of 
vascular proliferative lesions of the skin [53]. 
Until recently, the only described illness associated 
with B. quintana was trench fever, also known as 5-day 
fever, or quintana fever. The first cases were described 
in France among allied troops in 1915. The infection 
is transmitted by the human body louse, Pediculus 
humanus, probably via excreta entering the bloodstream 
through broken skin [54]. Clinical manifestations 
include cyclic fever occurring every 4-8 days, in 
association with periodic rigors, intense retro-orbital 
headache, pain in the long bones of the leg and the 
loins, restlessness, weakness, and insomnia. Symptoms 
range from very mild to severe. Successive relapses tend 
to diminish in severity and, although the duration of 
illness may be prolonged, i.e. 4-6 weeks, no fatalities 
have been recorded 1541. 
(c) The two predominant Bartonella pathogens, €3. 
henselue and B. quintanu, are now known to cause a 
range of human infections. These species do not cause 
disease in any host other than the human [54]. Their 
spectrum of infection is wide, and has been described 
in both immunocompetent and immunoconipromised 
individuals. Reported disease associations are summar- 
ized in Table 2. 
BA is a vascular proliferative disorder which most 
commonly causes lesions of the skin [54], but which 
also results in extracutaneous manifestations. Both B. 
henselae and B. quintana have been reported as causative 
[55]. Despite the lack of a proven animal reservoir for 
B. quintma, Tapper0 et a1 [56] postulate that BA is a 
zoonosis, based on a case-control study of 48 cases and 
94 matched controls. They demonstrated that, &om a 
long list of environmental factors, only traumatic cat 
contact (i.e. bite or scratch) was associated with BA by 
bivariate analysis, conferring a four-fold increased risk. 
PCR of 22 case patient tissues identified a genus- 
specific 16s rRNA fragment for Rochalimaeu in all 22. 
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Table 2 
Disease B. henselae B. quintana Reference 
Cat scratch disease 4- - See answer to Q lb  
Trench fcver - + See answer to Q3b 
Parenchymal bacillary peliosis i - 4,56,62,65,70 
Relapsing fever with bactereinia + + 4,5,33,84-86 
Chronic asymptomatic lymphadenopathy - + 87 
Bacillary angiomatosis (BA) + + 4,9,11,12,55-65,73 
Endocarditis i + 52,74-83 
The species were not identified. Furthermore, in HIV- 
infected patients, BA appears to be a manifestation of 
disseminated CSD [11,57-611. 
Although the first reports of BA were in HIV- 
infected patients, subsequent reports have described 
identical lesions in organ transplant recipients [4,12, 
58,62,63], and the immunocompetent [56,64,65]. 
Cutaneous lesions are usually multiple. They 
are characteristically red vascular papules or nodules 
when situated superficially, and non-colored nodules if 
present in the dermis or subcutaneous tissues [54,66]. 
Superficial lesions are distinguishable from Kaposi’s 
sarcoma (KS) on the basis of physical characteristics and 
histology [66]. Unlike those of KS, the lesions of BA 
are redder and blanch with pressure; they bleed if 
punctured, and are often painful. The diagnosis is made 
by histopathologic appearances of a biopsy, and the 
presence of the organisms by Warthin-Starry stain [66]. 
The lesions are indistinguishable from those of verruga 
peruana, and, interestingly, BA has not yet been reported 
in South America [54]. 
BA may present with extracutaneous manifesta- 
tions, ranging from lymphadenopathy to disseminated 
overwhelming infection. Involvement of the skin 
does not always occur with BA, but extracutaneous 
manifestations usually accompany skin lesions [54]. 
Lesions within the bone marrow, spleen, liver, respira- 
tory and gastrointestinal mucosa, heart, bone, voluntary 
muscle, and brain have been reported (references cited 
in Anderson [23], Maurin and Raoult [54] and Ada1 et 
A role for B. henselae in HIV-positive patients pre- 
senting with neurologic signs, including encephalo- 
pathy, has been mooted. BA of the central nervous 
system in this group of patients has been shown to be 
associated with intrathecal synthesis of specific antibody 
by an EIA which utilizes whole B. henselae as the 
antigen for detection of reactive antibodies [45,67]. 
Schwartzman et al demonstrated a 32% seroprevalence 
rate of antibodies to B. henselae among 50 HIV-positive 
patients with neurologic symptoms, only 29% ofwhom 
had abnormal computed tomography (CT) or magnetic 
a l  [661). 
resonance image (MRI) appearances, compared with 
4% of 51 HIV-positive controls without neurologic 
involvement [67]. The ratio of organism-specific anti- 
body concentration in CSF to that in serum confirmed 
intrathecal synthesis. Three patients had detectable IgM 
in CSF (of whom two also had detectable levels in 
serum), and P C R  of 16s rRNA fragments specific to 
B. henselae were positive in all three [67]. Symptoms 
ranged from cranial nerve palsies to ataxia, and from 
acute disorientation with hallucinations to progres- 
sive dementia. These findings suggest that B. henselae 
is a more common cause of neurologic disease in 
HIV-positive patients than is currently appreciated, 
particularly if C T  and M R I  imaging is normal. 
Initial experience suggests that prolonged therapy with 
erythromycin is effective [68,69]. 
Parenchymal bacillary peliosis is the broader term 
now used instead of bacillary peliosis hepatis (BPH) 
[54] to describe a syndrome which may occur as the 
sole manifestation of bartonella infection, or may be 
concomitant with BA or bacteremia [66]. Some authors 
consider it to be an extracutaneous manifestation 
of BA [23]. The syndrome is characterized by the 
development of cystic, blood-fded spaces within the 
parenchyma of, most commonly, the liver and also the 
spleen [54,62]. Patients present with gastrointestinal 
symptoms, such as nausea and vomiting, abdominal 
pain and distension, fever, chills, and hepatospleno- 
megaly. Diagnosis is by liver biopsy. Prior to its 
association with BA and HIV, bacillary peliosis had 
been described in patients with chronic diseases such as 
tuberculosis and terminal malignancies [54], and has 
now been described in immunocompetent patients 
[65]. To date, only B. henselae has been implicated in 
parenchymal bacillary peliosis [4,56,62,70]. 
Therapy is indicated for BA and parenchymal 
bacillary peliosis. Several agents have been reported 
to be effective, although it may be that the duration 
of therapy is more important than the choice of anti- 
biotic. Erythromycin appears to be particularly effective 
[4,11,33,57,58,60,62-65,711, especially if given for a 
period of at least 4-6 weeks. In practice, most authors 
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report the use of several agents given either in combi- 
nation or serially to achieve cure. Aminoglycosides 
[33,70], amoxycillin [33], co-trimoxazole [61,64], 
ceftriaxone [33], quinolones [5,33], chloramphenicol 
14,331 and rifampicin and isoniazid [11,57] have all 
been components of effective regimens. Doxycycline 
and tetracycline have been variously reported as 
successful [5,57,58,65,72] and ineffective [4,33]. 
(d) In a review of 299 cases of infective endocarditis of 
all causes, Raoult et al attributed 10 cases (3%) to 
Bartonella spp. [74]. Bartonella endocarditis has been 
reported in at least 34 patients [52,74-831, of whom 
only five were female. The age of the male patients 
ranged from 22 to 59 years, while the females tended 
to be older, ranging from 45 to 81 years. Eighteen 
patients were homeless and/or alcoholic; 15 were im- 
munocompetent; and one was HIV positive. All cases 
were of native valve endocarditis, 15 with predisposing 
valvular factors, such as a bicuspid aortic valve. The 
aortic valve was by far the most common valve affected; 
indeed, only three cases were non-aortic, affecting the 
mitral valve alone. Six cases had dual-valve infection: 
aortic plus mitral in four; and aortic plus tricuspid in 
two. B. quintana was implicated in 13 cases [74,75, 
77,78,80,82,83], B. henselae in seven [74,76,79,81], and 
B. elizabethae in one 1521. In 13 cases, the species was 
not determined. Infection with B. quintana, in contra- 
distinction to that with B.  henselae, occurred pre- 
dominantly among patients without a predisposing 
valvular lesion, and in those who were homeless. B. 
quintana is known to be transnlitted by an arthropod 
vector in environments of overcrowding and poor 
hygiene, conditions similar to those experienced by the 
homeless. Valvular lesions were visualized in 30 of the 
cases by echocardiography, and surgery was required 
in all but four, of whom two died, one was cured by 
antibiotics alone, and one absconded. Eight patients, of 
the 29 whose outcomes were known, died. 
Raoult et a1 report an IFAT titer of 1:1600 or 
greater to have a positive predictive value for endo- 
carditis of 0.884 [74]. Bartonellae were isolated from 
blood in 12 cases [52,74,75,77-791. Culture of valve 
tissue was successful only once [74]. In contrast, PCR 
on valve tissue looks more promising. In Raoult and 
colleagues’ report of 22 new cases of bartonella 
endocarditis, six of 16 valves tested yielded citrate 
synthase aniplicons (see answer to Q 6 e )  [74], fresh 
tissue proving more ‘fertile’ than paraffin-embedded 
specimens. Prior to this report, PCR had been valuable 
in making the diagnosis in nine cases out of 12 
Experience in the treatment of endocarditis is 
limited. Overall, a combination of a (3-lactani (e.g. 
[75,76,78,79,81-831. 
aminopenicillin or ceftriaxone) and an aminoglycoside 
(e.g. gentamicin or netilmicin) for a duration of 
4-6 weeks has been used most frequently, commonly 
with an oral macrolide, doxycycline, rifampicin or 
4-quinolone added towards the end of the course to 
enable continued therapy for up to 3 months. In 
combination with valve replacement, these regimens 
are usually effective [74]. It is clear that bartonella 
endocarditis tends to be very destructive to the valve, 
and experience suggests that valve replacement is almost 
inevitable. Suspicion of the diagnosis, therefore, should 
be raised early in the case of a ‘culture-negative’ 
endocarditis. 
(e) A syndrome of relapsing fever due to persistent 
bacteremia has been described, and is not confined 
to the immunocompromised. At least 28 patients 
have been described with this syndrome of bartonella 
infection [3-5,33,84-861. Six patients were previously 
healthy, including an 8-year-old child; 12 were 
immunosuppressed (HIV-infected, nine; therapy for 
organ transplantation, two; splenectomy for thalassemia, 
one); and ten were homeless, chronic alcoholics. With 
the exception of one HIV-infected patient, the B. 
quintana isolates were identified only in the homeless 
group. 
HIV-negative individuals, even if pharmacologically 
immunosuppressed, experience an abrupt onset of fever 
and rigors which usually responds, without relapse, to 
short courses of antibiotics. By contrast, HIV-positive 
patients tend to present with an insidious illness charac- 
terized by malaise, weight loss, fatigue, and recurring 
fevers of gradually increasing magnitude, and require 
therapy for at  least a month [4]. 
Question 4 
(a) Bartonella spp. are not obligate intracellular patho- 
gens, a key factor in the proposal to remove the genus 
from the order Rickettsiales [51], although cell-culture 
systems have been useful in the isolation of these 
organisms [55,75,79,87]. 
(b) B. henselae, in common with B. quintana and B. 
elizabethae, is a fastidious aerobic, slightly curved, Grani- 
negative bacillus, which is oxidase and catalase negative. 
Classically, B. henselae exhibits ‘twitching’ motility in a 
wet mount, although it does not possess flagella (881. 
A j p i a  spp. differ by being urease and oxidase positive, 
and by reducing nitrates 1881. 
(c) The species causing human disease fall into two 
basic phenotypic groups: B. bacillijhnis and the non- 
bacillformis group. The differential features are sum- 
marized in Table 3 123,881. 
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Table 3 
Property 
B. henselae, B. quintma, 
B. bacill+rmis B. elizabethae 
- Catalase + 
- Flagella + 
Optimal growth + 5% COz - + 
Optimal growth temperature 25-28°C 34-37OC 
Colony size <1 mIn 21 111111 
(d) Bartonella spp. do not produce acid from carbo- 
hydrates [88], and conventional phenotypic tests are 
largely unhelpful as a means of species identification. 
They do exhibit peptidase activity with certain amino 
acid substrates [1,4] which is detectable with the RapID 
ANA I1 system (Innovative Diagnostic Systems, Atlanta, 
GA, USA) and the Rapid Yeast Identification Panel 
(Baxter Healthcare, West Sacramento, CA, USA) 
[l]. One group was able, with careful adjustment of 
inoculum concentration, to differentiate B. henselae 
from B. quintana on the basis of biotype using the 
MicroScan Rapid Anaerobe Panel (Baxter Diagnostics, 
Deerfield, IL, USA) [84]. Gas-liquid chromatography 
of methyl ester derivatives has also been used to 
differentiate the species on the basis of their cellular 
fatty acid composition [1,4,88], although the differ- 
ences are very small and of little practical value for 
confident identification to the species level [54]. 
Genotypic methods have therefore become the 
mainstay of differentiation between the species, parti- 
cularly DNA-DNA hybridization [23,54]. However, 
in practical clinical terms, species identification is often 
unnecessary, since in certain conditions, such as CSD, 
once the diagnosis is made by identification of the 
genus, the species can be inferred. Furthermore, in 
diseases caused by more than one species, the prognosis 
and treatment do not appear to be affected by species. 
(e) Bartonella spp. stain with acridine orange, and some 
studies have suggested utilizing this technique on 
blood culture smears from conventional bottles as a 
means of making an early presumptive identification 
[85,89,90]. Organisms can be detected after 7 or 8 days 
of incubation, but subculture is still necessary for 
confirmation of identity. The Gimenez stain is also 
useful [3]: Bartonellae stain with carbol fuchsin, while 
host cells and debris stain with malachite green. 
Question 5 
(a) The optimal method for isolation of Bartonella 
spp. has not yet been described. Broadly spealung, two 
main approaches have been used: first, cell-culture 
techniques [55,75,79,87], and second, a variety of 
broth and/or solid medium systems [5,55,75,85,86]. 
There has been no comparative study of these diverse 
methods to assess their relative sensitivities. 
(b, c) Some standard media, such as chocolate agar and 
blood agar, will support the growth of Bartonella spp. 
with extended incubation in the appropriate atmo- 
sphere [5,52,75,77,78,84,85]. However, Bartonella spp. 
are known to exhibit hemin dependence [91,92] and 
therefore will not grow on meha such as MacConkey 
agar, tryptic soy agar, yeast extract agar, or brain-heart 
infusion broth [91], unless supplemented with blood, 
preferably horse or rabbit rather than sheep [4,55]. 
Subculture of blood onto solid agar can result in 
colonies being detected within 4 days ofincubation [4], 
although 1-2 weeks is more usual [52,77,78]. 
B. henselae has been successfully retrieved by direct 
plating of lysis-centrihged blood [3,4,33], lymph node 
homogenate [21,22] and cutaneous lesion [SS] onto 
blood-containing standard media. B. quintana has also 
been retrieved from lysis-centrifuged blood by direct 
plating [55]. Culture of blood, lymph node, cutaneous 
lesions and even osseous lesions in a cell-line system 
prior to subculture onto solid agars appears to provide 
an improved yield [55,75,87]. Attempts at both direct 
culture and cell-line culture of cardiac valve tissue have 
proven to be largely unsuccessful. 
(d) In cases of endocarditis, relapsing fever and systemic 
infection in the immunocompromised, bacteremia is 
relatively common, and Bartonella spp. may be recover- 
able from blood. Automated blood culture systems (e.g. 
BACTEC, Becton Dickinson Diagnostic Instrument 
Systems, Sparks, MD, USA, and BacT/Alert, Organon 
Teknika, Durham, NC, USA) have been successful in 
recovering organisms [52,56,77,80,85,86], but it is 
generally recommended that detection of growth by 
COz production is not reliable because these organisms 
produce insufficient quantities [33,52,78,85]. Instead, 
subculture from the blood culture bottle onto solid 
media, usually after 1 week of initial incubation, and 
repeated at intervals, is the approach described most 
often. Prolonged incubation for 4-6 weeks or more 
may be necessary. Some groups report the superiority 
of direct plating of lysis-centrifuged blood over the 
BACTEC type method [4,33]. 
(e) Fresh isolates of B. henselae, B. quintana and B. 
elizabethae produce small white colonies, often with 
variable morphology (Figure 1). They are autoadherent 
to the agar, and corrosive pitting of the surface has 
been described [3,52,55]. This feature is thought to 
be due to type IV pili on the exterior of the cell 
wall [93]. Subculture of the colonies leads to loss of 
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Figure 1 Bavforwlln / I C ~ L W / U ~  showing variable colony tnorpholog on blood agar after 5 days of incubation i n  S'X, CO? 3t 
37 "C (courtesy of Dr T. E l .  Koh, Royal London Hospital). We gratefully acknowledge SniithKline Bcccham I'liarmaceuticnls, 
UK, whose provision of an Educational Grant permits us to reproduce color illustrations for Continuing Education Jrticlec. 
autoadherence and more rapid growth. B. bacill$ormis 
colonies tend not to be adherent, and are snialler and 
translucent 1231. 
Question 6 
(a) Histopathologic examination of  biopsy speciniens 
has been, and remains, one of  the cornerstones of diag- 
nosis of bartonella infection, because of  the inherent 
difficulties of culture. Wxthin-Starry silver staining, 
initially used for the visualization of spirochetes, was 
iiisti-uniental in establishing CSD and BA as infectious 
diseases due to Bartortella spp. [6,7,9,11,55,57,66]. 
T h e  stain enables differentiation from other causes of 
lyiiipliadeti[)€~atliy and similar skin lesions, particularly 
KS. 
(b) Light microscopy of  biopsy specimens denion- 
stratrs characteristic changes with both BA and CSD. 
In the former there is lobular proliferation of  blood 
vessels seen with hematoxylin and eosin staining, and 
infiltration with neutrophils containing granular aggre- 
gates which are clumps of  bacteria [23].  Granuloma 
formation is not a feature ofBA. By contrast, the lymph 
nodes of  patients with CSD typically show stellate 
caseating granulomas, niicroabscesses, and follicular 
hyperplasia 1341. 
(c) T h e  CSD skin test uses heat-inactivated material 
obtained from the lymph node of a patient already 
diagnosed. The preparation is injected intradermally, 
and the reaction read 48-96 h later. Of patients with 
a clinical diagnosis of CSL), 95-98'% are positive for 
the test [23]. However, becauw of safety concerns 
regarding the use of human-derived products, and the 
lack of general availability, this test is of  limited value. 
(d) Theoretically, serologic testing is the most practical 
method of  diagnosing bartonella infection. Indirect 
initnunofluorescent antibody tests (IFAT) and enzyme- 
linked ininiunosorbent assays (ELISA) have been 
developed, and have played a pivotal role in identifying 
the cause of  CSL) (see answer to Q1 b). However, there 
are drawbacks to serologic testing. Most HIV-infected 
patients fail to mount a detectable antibody response 
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1541, which renders the tests unhelpful in this important 
group of patients. Even among immunocompetent 
individuals, detectable antibody may not be present. 
A recent report evaluating the IFAT in a small number 
of patients diagnosed with CSD by the strictest criteria 
(n=91) found a titer of 1:64 or higher in 9596, 
compared with around 4% of controls [94]. However, 
other reports have found less satisfactory detection rates 
of around 84-88% 116,171. In patients for whom paired 
sera were available, only 66% demonstrated a four-fold 
rise or fall in titer (n=132) [94]. A recent report 
evaluating an ELISA test concluded that the IgM assay 
was less sensitive than the IFA equivalent, and that 
the IgG assay was not sensitive enough for diagnosis 
Even in cases where a significantly raised antibody 
titer is present, e.g. in bartonella endocarditis, the 
specificity of the antibody tests is frequently poor. Not 
only are there reported difficulties in differentiating 
between B. henselae and B. quintana [75,80,81] but 
significant cross-reactivity with Coxiella burnetii [9S] 
and Chlamydia pneumoniae [75,96] has been reported. 
Indeed, Raoult et a1 [74] found that nine patients 
previously diagnosed to have chlamydial endocarditis 
on the basis of serologic investigation had in fact 
been infected with Bartonella spp. following antibody 
adsorption assays. 
~151. 
(e) Genotypic methods are perhaps the most robust 
means of differentiating Bartonella spp. and PCR offers 
the major advantage of rapid identification directly 
from clinical samples. However, these techniques are 
largely unavailable in routine diagnostic laboratories. 
DNA-DNA hybridization is considered to be the 
standard and has been instrumental in the recent 
taxonomic changes which have taken place in relation 
to this and associated genera [Sl]. Other techniques 
found to be of value include 16s rRNA gene sequenc- 
ing, citrate synthase gene analysis, and pulsed-field gel 
electrophoresis (PFGE) of genomic DNA. 
The 16s rRNA gene sequences for the eight 
species so far sequenced are very similar but diverse 
enough to allow RFLP of amplified genes with enzymes 
known to act in the regions of greatest diversity. This 
has provided a very useful method for the identification 
of new species 1971. Another scheme utilizes a PCR- 
based RFLP analysis of the citrate synthase gene to 
differentiate Bartonella spp. from the other fastidious 
Gram-negative causes of ‘culture-negative’ endocarditis 
1901. It was proposed that this technique could be 
employed on blood culture supernatants which stained 
positively with acridine orange. 
SUMMARY 
Bartonella spp. are increasingly identified as the cause 
of human infection in a wide range of manifestations. 
Although reports are largely contemporary, this may 
simply reflect the difficulties in culturing the organisms, 
and the relatively recent evolution of genotypic tech- 
niques. Nevertheless, we can conclude that, whether 
the reported incidence is escalating artifactually or 
genuinely, Bartonella spp. are likely to account for more 
cases of infection than we currently detect. 
Given that we know that Bartonella spp. are capable 
of causing life-threatening infection in both immuno- 
suppressed and immunocompetent individuals, it is 
clear that our collective meter of suspicion needs to be 
re-tuned to be more sensitive. Particularly in certain 
clinical situations, such as ‘culture-negative’ endocarditis, 
the ‘culture-negative’ immunosuppressed patient with 
refractory fever, and the AIDS patient with neurologic 
signs in whom first-line investigation is negative, greater 
efforts are required to positively identify these organisms. 
Answers to the multiple-choice questions 
41: a. True; b. True; c. False; d. False; e. True 
4 2 :  a. False; b. True; c. True; d. True; e. False 
4 3 :  a. True; b. True; c. True; d. True; e. False 
44: a. False; b. False; c. True; d. True; e. True 
45: a. False; b. True; c. True; d. True; e. True 
4 6 :  a. True; b. False; c. True; d. False; e. True 
Further reading 
Readers are referred to two excellent comprehensive 
reviews by Anderson and Neuman 1231 and Maurin 
and Raoult 1541. 
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